SCHEMBL1458952

SCHEMBL1458952

Cc1ccc(CC(=O)N[C@@H](Cc2ccccc2)C(=O)O)cc1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PSMB8 P28062 4/20 0.67
▸ PSMB5 P28074 4/20 0.67
▸ CNR1 P21554 1/20 0.62
▸ CNR2 P34972 1/20 0.62
▸ ITGB3 P05106 1/20 0.60
▸ ITGA2B P08514 1/20 0.60
▸ CTSL P07711 1/20 0.59
▸ CTSB P07858 1/20 0.59
▸ CTSS P25774 1/20 0.59
▸ KEAP1 Q14145 1/20 0.57
▸ NFE2L2 Q16236 1/20 0.57
▸ L3MBTL1 Q9Y468 1/20 0.56
▸ ACE P12821 3/20 0.56
▸ KMT2A Q03164 2/20 0.54
▸ MEN1 O00255 1/20 0.54
▸ GAA P10253 1/20 0.53
▸ MAPT P10636 1/20 0.53
▸ MME P08473 2/20 0.52
▸ CPA1 P15085 1/20 0.52
▸ ACE2 Q9BYF1 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1459346 1.00 PSMB8 (0.67) PSMB8PSMB5CNR1CNR2ITGB3
SCHEMBL10504767 0.91 ITGB3 (0.65) PSMB8PSMB5CNR2ITGB3ITGA2B
SCHEMBL4144668 0.91 ITGB3 (0.65) PSMB8PSMB5CNR2ITGB3ITGA2B
SCHEMBL4144665 0.91 ITGB3 (0.65) PSMB8PSMB5CNR2ITGB3ITGA2B
SCHEMBL8704621 0.89 MME (0.60) PSMB8PSMB5CNR1CNR2ACE
SCHEMBL1458962 0.88 TACR1 (0.56) PSMB8PSMB5CNR1CNR2ITGB3
SCHEMBL1458913 0.88 TACR1 (0.56) PSMB8PSMB5CNR1CNR2ITGB3
SCHEMBL1459337 0.88 TACR1 (0.56) PSMB8PSMB5CNR1CNR2ITGB3
SCHEMBL14816081 0.87 ATM (0.69) PSMB8PSMB5CNR1CNR2CTSL
SCHEMBL14205009 0.87 ATM (0.69) PSMB8PSMB5CNR1CNR2CTSL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8822698-B2 Aminoacid derivatives, their process of preparation and their therapeutical uses as inhibitors of oncogenic signals by the Met family UNIVERSITE D'AIX-MARSEILLE (FR) 2014-09-02 — — US disclosed
US-8822698-B2 Aminoacid derivatives, their process of preparation and their therapeutical uses as inhibitors of oncogenic signals by the Met family UNIVERSITE D'AIX-MARSEILLE (FR) 2014-09-02 — — US disclosed
US-20130085143-A1 AMINOACID DERIVATIVES, THEIR PROCESS OF PREPARATION AND THEIR THERAPEUTICAL USES AS INHIBITORS OF ONCOGENIC SIGNALS BY THE MET FAMILY UNIVERSITE D'AIX-MARSEILLE (FR) 2013-04-04 — — US disclosed
EP-2483280-A1 NEW AMINOACID DERIVATIVES, THEIR PROCESS OF PREPARATION AND THEIR THERAPEUTICAL USES AS INHIBITORS OF ONCOGENIC SIGNALS BY THE MET FAMILY Université d'Aix-Marseille (FR) 2012-08-08 — — EP disclosed
WO-2011036303-A1 NEW AMINOACID DERIVATIVES, THEIR PROCESS OF PREPARATION AND THEIR THERAPEUTICAL USES AS INHIBITORS OF ONCOGENIC SIGNALS BY THE MET FAMILY UNIVERSITE DE LA MEDITERRANEE AIX-MARSEILLE II (FR) 2011-03-31 — — WO disclosed
WO-2011036303-A1 NEW AMINOACID DERIVATIVES, THEIR PROCESS OF PREPARATION AND THEIR THERAPEUTICAL USES AS INHIBITORS OF ONCOGENIC SIGNALS BY THE MET FAMILY UNIVERSITE DE LA MEDITERRANEE AIX-MARSEILLE II (FR) 2011-03-31 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130085143-A1 AMINOACID DERIVATIVES, THEIR PROCESS OF PREPARATION AND THEIR THERAPEUTICAL USES AS INHIBITORS OF ONCOGENIC SIGNALS BY THE MET FAMILY MET, HGFAC, HRAS PSMB8 1911/4885PSMB5 2538/4885CNR1 4595/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback